Opdivo® (nivolumab) – New indication
June 10, 2020 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Top